Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies

ABSTRACT: Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies

PROVIDER: PRJNA909822 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies [CITE-seq]

Project description:Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies [CITE-seq]

| PRJNA909824 | ENA

Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies [CRISPR Screen]

Project description:Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies [CRISPR Screen]

| PRJNA843099 | ENA

Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies [CRISPR Screen]

Project description:Following nearly five decades with few approved therapies for acute myeloid leukemia (AML), the last three years have brought stellar progress with the U.S. Food and Drug Administration approving a number of new therapies for AML patients. Despite these advances, there are several high-risk patient AML populations with dismal survival on the order of months including those with primary refractory disease, those whose AML developed from an antecedent hematologic disorder, and those with high risk cytogenetic or mutational profiles (such as TP53 mutations or a complex karyotype). Furthermore, therapeutic options are limited for those unfit to receive cytotoxic chemotherapy due to age or co-morbidities. These treatment challenges clearly illustrate the need for improved therapeutic approaches in AML. Here we identify that antibody therapies for AML can be enhanced via optimization of (1) Fab target selection, and (2) engineering the Fc portion of the antibody to maximally engage receptors on immune effector cells. We demonstrate that antibodies targeting a novel AML-specific cell surface marker known as U5 snRNP200 have therapeutic efficacy in AML. Finally, we performed a whole-genome CRISPR screen to identify mechanisms by which U5 snRNP200 traffic to the cell surface. This revealed a requirement for cell-surface CD32a to enable U5 snRNP200 cell membrane localization.

2022-12-02 | GSE205028 | GEO

Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies [CITE-seq]

2022-12-08 | GSE220473 | GEO

Developing & Optimizing Acute Myeloid Leukemia Specific Therapeutic Antibodies

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-12-07 | GSE220474 | GEO

Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies

Project description:Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies

| PRJNA391729 | ENA

Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies VI

Project description:Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies VI

| PRJNA391738 | ENA

Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies II

Project description:Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies II

| PRJNA391734 | ENA

Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies V

Project description:Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies V

| PRJNA391737 | ENA

Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies III

Project description:Therapeutic antibodies to ganglioside GD2 evolved from highly selective germline antibodies III

| PRJNA391735 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data